{
    "id": 32735,
    "fullName": "EGFR V1010_D1152del",
    "impact": "deletion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR V1010_D1152del results in the deletion of 143 amino acids in the cytoplasmic domain of the Egfr protein from amino acids 1010 to 1152 (PMID: 22001862). V1010_D1152del results in constitutive phosphorylation of Egfr, Stat5, Shc, and Src, is transforming in cell culture, and promotes tumor growth in mouse models (PMID: 22001862).",
            "references": [
                {
                    "id": 18090,
                    "pubMedId": 22001862,
                    "title": "Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22001862"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "V1010_D1152del",
    "createDate": "03/10/2020",
    "updateDate": "03/10/2020",
    "referenceTranscriptCoordinates": {
        "id": 188312,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55201269_55205440del4172",
        "cDna": "c.3028_3456del4172",
        "protein": "p.V1010_D1152del143",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20853,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited viability of transformed cells expressing EGFR V1010_D1152del in culture (PMID:22001862).",
            "molecularProfile": {
                "id": 35365,
                "profileName": "EGFR V1010_D1152del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18090,
                    "pubMedId": 22001862,
                    "title": "Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22001862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20852,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited viability of transformed cells expressing EGFR V1010_D1152del in culture (PMID:22001862).",
            "molecularProfile": {
                "id": 35365,
                "profileName": "EGFR V1010_D1152del"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18090,
                    "pubMedId": 22001862,
                    "title": "Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22001862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20854,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited tumor growth in cell line xenograft models of glioma expressing EGFR V1010_D1152del, and resulted in modest improvement of survival compared to control (60.5 vs 55.5 days, p=0.04) in an orthotopic brain tumor model (PMID: 22001862).",
            "molecularProfile": {
                "id": 35365,
                "profileName": "EGFR V1010_D1152del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18090,
                    "pubMedId": 22001862,
                    "title": "Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22001862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20855,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited tumor growth in cell line xenograft models of glioma expressing EGFR V1010_D1152del, and prolonged survival in an orthotopic brain tumor model (PMID: 22001862).",
            "molecularProfile": {
                "id": 35365,
                "profileName": "EGFR V1010_D1152del"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18090,
                    "pubMedId": 22001862,
                    "title": "Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22001862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35365,
            "profileName": "EGFR V1010_D1152del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188312,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55201269_55205440del4172",
            "cDna": "c.3028_3456del4172",
            "protein": "p.V1010_D1152del143",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}